Jan 8, 2024
MediSieve is Part of Change Makers, by The Royal Society of Chemistry
MediSieve is accepted to a highly selected RSC ecosystem of deeptech ventures.
LONDON, January 8, 2024 – MediSieve is proud to announce its selection to join the prestigious Change Makers ecosystem, an initiative by the Royal Society of Chemistry. This recognition is part of a dynamic entrepreneurial ecosystem that supports deep tech ventures with the potential to positively impact global challenges.
MediSieve's inclusion in this program highlights its commitment to innovative healthcare solutions through its groundbreaking Magnetic Blood Filtration technology. The Change Makers ecosystem, focusing on holistic support for ventures tackling systemic issues in deep tech, aligns perfectly with MediSieve's vision of addressing critical health issues.
"We are deeply honored to be part of the Change Makers and grateful to Andy Waterworth, Ben Voysey, and the RSC team for this opportunity," said MediSieve's CEO, Dr George Frodsham. "This affiliation not only acknowledges our technological potential but also aligns us with a network dedicated to creating substantial change through deep tech chemistry."
The Royal Society of Chemistry’s Change Makers is a beacon for ventures aiming to make significant environmental, social, and economic impacts. It emphasises the value of deep tech chemistry in policy and investment, fostering an environment where innovation meets practicality for the betterment of society.
About Magnetic Blood Filtration
MediSieve's Magnetic Blood Filtration Platform is intended to enable the rapid and specific depletion of specific agents from the bloodstream of patients. The extracorporeal therapy uses therapeutic Magnetic Beads that are designed to bind specifically to the clinical target. The Beads are introduced into the extracorporeal circuit during the therapy, mixing with the patient’s blood and binding to the clinical targets. The Capture System captures all the Magnetic Beads and bound targets, preventing their return to the patient.
About MediSieve
MediSieve is a London-based BioTech start-up that has developed Magnetic Blood Filtration, a revolutionary platform therapy that enables the physical removal of specific substances from the bloodstream of patients. It can be used (1) as a direct treatment, (2) to increase the safety and efficacy of other therapies, or (3) to enable personalised medicine. The company is a spin-off from University College London and is developing its products at the White City Innovation District in West London. MediSieve is actively seeking investment and partnerships.
MEDIA CONTACT:
Alina Kagermazova
INVESTOR AND PARTNERSHIP CONTACT:
George Frodsham
